Insights2023-05-08T11:22:43-04:00

PRECISIONadvisors Recognized as a Vault Top Ranked Consulting Firm

PRECISIONadvisors has been recognized as a Vault Top Ranked Consulting Firm! This marks PRECISIONadvisors' inaugural appearance on the prestigious Vault Consulting 50 list, which evaluates firms based on confidential employee input covering aspects such as workplace culture and quality of life.​ The firm secured rankings in four distinct categories:​ Vault Consulting 50 North America​ Best Boutique Consulting Firms​ Best Consulting Firms for Women​ Best Consulting Firms for Formal Training​

LEARN MORE

LEARN MORE

PRECISIONadvisors New Office Opening in London

The PRECISIONadvisors team is looking forward to welcoming clients and Precision colleagues to their new office opening this week. The client networking event includes a panel discussion on the evolving marketing access environment in the UK featuring Andrew Walker, David Watson and Neil Grubert. Reach out to Richard Macaulay to attend! * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15

LEARN MORE

LEARN MORE

Conference: ISPOR Europe 2023

Precision will be at ISPOR Europe, November 12-15, 2023. * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15

LEARN MORE

LEARN MORE

How High Can Prices Go? Cell and Gene Therapies

Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.

LEARN MORE

LEARN MORE

China’s NRDL 2022 Update: Spotlight on Rare Disease (Part 3 of 3)

With negotiated prices as much as 95% below launch pricing, marketing rare disease therapies in China is a challenge. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan discuss alternate access channels. Download the free brief (part 3 of 3).

LEARN MORE

LEARN MORE

China NRDL 2022 Update – Spotlight on Oncology (Part 2 of 3)

Recent updates to China’s NRDL have a big impact on oncology therapies. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what that means for multinationals in this free brief (part 2 of 3). 

LEARN MORE

LEARN MORE

On Demand: NICE Early Scientific Advice: When, Why, and How!

Have you considered using NICE Scientific Advice (SA) to inform your evidence development, trial design, and/or economic modelling? Are you familiar with the concept of NICE SA, but have no direct experience? Or have you used the process before, but want to learn how to optimise your use of it? Join PRECISIONadvisors on July 26 at 9am EST for a complimentary webinar, as we share our experience with NICE SA in a pragmatic discussion of what it can do for you, and best practices for getting the most from NICE SA.

LEARN MORE

LEARN MORE

On Demand: Cell and Gene Therapies – How High Can Prices Go?

This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).

LEARN MORE

LEARN MORE

On Demand Webinar – Paying for Prevention? Payer Access Challenges and Solutions for Preventative Gene Therapies

Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.

LEARN MORE

LEARN MORE

How High Can Prices Go? Cell and Gene Therapies

Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.

LEARN MORE

LEARN MORE

White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions

Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.

LEARN MORE

LEARN MORE

New White Paper: Speeding up Patient Access to Innovation: Strategies to Convert Early European Regulatory Approval Into Optimal Reimbursement

Efforts to facilitate patient access to innovative medicines have taken on new urgency in the pandemic era, sharpening drug developers’ focus on the first step in this process: securing regulatory approval.

LEARN MORE

LEARN MORE

PRECISIONadvisors Recognized as a Vault Top Ranked Consulting Firm

PRECISIONadvisors has been recognized as a Vault Top Ranked Consulting Firm! This marks PRECISIONadvisors' inaugural appearance on the prestigious Vault Consulting 50 list, which evaluates firms based on confidential employee input covering aspects such as workplace culture and quality of life.​ The firm secured rankings in four distinct categories:​ Vault Consulting 50 North America​ Best Boutique Consulting Firms​ Best Consulting Firms for Women​ Best Consulting Firms for Formal Training​

LEARN MORE

LEARN MORE

PRECISIONadvisors New Office Opening in London

The PRECISIONadvisors team is looking forward to welcoming clients and Precision colleagues to their new office opening this week. The client networking event includes a panel discussion on the evolving marketing access environment in the UK featuring Andrew Walker, David Watson and Neil Grubert. Reach out to Richard Macaulay to attend! * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15

LEARN MORE

LEARN MORE

Conference: ISPOR Europe 2023

Precision will be at ISPOR Europe, November 12-15, 2023. * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15

LEARN MORE

LEARN MORE

Access90: Chloe Wang

For pharma companies, NRDL is the primary route of reimbursement in China—and the rules have changed. Find out how, in this 2-minute video with Chloe Wang, PRECISIONadvisors Analyst and a member of the China Centre of Excellence.

LEARN MORE

Access90: Salvador Alvarez Rio

With the Latin American pharma market expected to grow 10% in the next two years, it pays to gain access. But how? Salvador Alvarez Rio, Senior Engagement Manager at PRECISIONadvisors, explains the power of patient advocacy groups to insist on reimbursement for high-cost advanced medicines.

LEARN MORE

Access90: William Derrickson

Dystrophic Epidermolysis Bullosa (DEB) is an ultra rare genetic disease with no currently approved treatments. In this Access90, Precision's Will Derrickson discusses the unique market access considerations for Krystal Biotech's anticipated launch of B-VEC, a non-invasive treatment for DEB and the first ever topical gene therapy.

LEARN MORE

Are YOU ready to make the most of China’s evolving pharmaceutical reimbursement landscape?

China, the second largest pharmaceutical market in the world (valued at more than $150 billion),  is experiencing a paradigm shift characterized by a booming economy, a growing middle class, and an increasingly aged population with rising disease rates. By reviewing recent changes to the Chinese pricing and market access landscape, PRECISIONadvisors’ Andrea Ong and Laura Montani discuss how manufacturers can capitalize on this booming market.

LEARN MORE

On Demand: Cell and Gene Therapies – How High Can Prices Go?

This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).

LEARN MORE

Article: The Future of Gene Therapies: Three Trends

Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision's Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.

LEARN MORE